Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...

This last patient was included because of the biological similarity between atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. 15 (39%) patients had high-risk cytogenetics ...

European biotech argenx (Euronext: ARGX) has secured European Commission approval for Vyvgart (efgartigimod alfa) in chronic ...

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

The Australian swimming legend and triple Olympian opens up about finding hope and courage in the face of a chronic health ...

Nasdaq-listed shares of argenx SE (ARGX) rose 2% by Friday afternoon after the company announced that the European Commission ...

VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDPApproval based on ADHERE clinical trial, the ...

A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare ...

A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare ...